Trial Profile

Pilot Study of the Efficacy and Safety of CD19 Targeted Chimeric Antigen Receptor Engineered T Cell in the Treatment of Relapsed or Refractory CD19 Positive Acute Myeloid Leukemia (AML)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 18 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti-CD19 chimeric antigen receptor T cell therapy Shanghai Unicar Therapy Bio-medicine Technology (Primary)
Indications Acute myeloid leukaemia
Focus Adverse reactions
Sponsors Shanghai Unicar-Therapy Bio-medicine Technology

Most Recent Events

27 Nov 2023 Planned End Date changed from 28 Jan 2024 to 31 Dec 2025.
27 Nov 2023 Planned primary completion date changed from 18 Jan 2023 to 31 Dec 2024.
18 May 2022 Planned End Date changed from 28 Jan 2022 to 28 Jan 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com